Close Menu

NEW YORK (GenomeWeb) – HIV-1 can acquire resistance to editing by CRISPR/Cas9 in CD4+ SupT1 cell lines, according to the results of a new study, and in fact, it's the mechanics of the Cas9 enzyme that allows the virus to acquire benign mutations that ultimately render gene editing useless.

Led by McGill University Professor Chen Liang, the study's authors showed that while CRISPR/Cas9 can efficiently target and excise proviral DNA integrated in the host genome, gene editing can lead to mutations that allow the virus to persist in some cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.